A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Tejaswi V MudigondaKenneth WymanDavid R SpigelKimberly B DahlmanF Anthony GrecoIgor PuzanovMark C KelleyJohn D HainsworthJeffrey A SosmanDouglas B Johnson

Published in: Pigment cell & melanoma research (2015)

Keyphrases

advanced non small cell lung cancer
metastatic colorectal cancer
epidermal growth factor receptor
open label
placebo controlled
tyrosine kinase
clinical trial
randomized controlled trial
double blind